

RESEARCH

Open Access



Restore natural fertility of *Kit^W/Kit^{WV}* mouse with nonobstructive azoospermia through gene editing on SSCs mediated by CRISPR-Cas9

Xiaoyu Li^{1,2*†}, Tiecheng Sun^{2†}, Xiuxia Wang², Jixin Tang^{1,2} and Yixun Liu^{2*}

Abstract

Background: Male infertility is a serious social problem in modern society. Nonobstructive azoospermia (NOA) caused by germ cell gene defects is an important reason for male infertility, but effective clinical treatment for this disease has not been established.

Methods: We choose *Kit^W/Kit^{WV}* mouse as a research model and try to develop a new treatment strategy and “cure” its infertility. Mutant spermatogonial stem cells (SSCs) were isolated from one single unilateral testis of a 14-day-old *Kit^W/Kit^{WV}* mouse and propagated in vitro. The C to T point mutation on *Kit^{WV}* site of these SSCs was corrected through CRISPR-Cas9-mediated homology-directed repair (HDR) in vitro. Then, the repaired SSCs were screened out, proliferated, and transplanted into the remaining testis, and complete spermatogenesis was established in the recipient testis.

Results: Healthy offsprings with wild type *Kit* gene or *Kit^W* mutation were obtained through natural mating 4 months after SSC transplantation.

Conclusion: In this study, we established an effective new treatment strategy for NOA caused by germ cell gene defects through a combination of SSC isolation, CRISPR-Cas9-mediated gene editing, and SSC transplantation, which brought hope for these NOA patients to restore their natural fertility.

Keywords: CRISPR-Cas9, Nonobstructive azoospermia, Spermatogonia stem cells

Background

Male infertility has become an increasingly serious social problem in modern society, and nonobstructive azoospermia (NOA), which accounts for 10% of all infertile men, is an important cause for this [1–3]. Genetic causes, including chromosomal aberrations and spermatogenesis gene mutations, are often detected on severe NOA patients [4]. Gamete-deficient NOA due to germ cells' genetic mutations, such as *RBMY* [5], *KLHL10* [6], and *SYCP3* [7], has been incurable by assisted reproductive technologies and difficult to bear for patients [8]. Cell

therapies are considered to be one of the most promising strategies to rescue this type of infertility [9].

c-Kit is expressed in germ cells and controls germ cell differentiation in mammalian testis [10]. Heterozygous mutant mice with *W* and *WV* mutation of this gene, the *Kit^W/Kit^{WV}* mice, whose spermatogonia are considerably reduced or exhausted, have been used as an excellent animal model to develop therapeutic strategies for gamete-deficient patients due to genetic mutations by Yuan et al [9]. They isolated tail-tip fibroblasts from adult *Kit^W/Kit^{WV}* mice and then derived embryonic stem cells from these cloned blastocysts obtained by somatic cell nuclear transfer. The produced mutant ESCs' *W* site was corrected using TALEN-mediated gene editing and further differentiated into primordial germ cell-like cells in vitro and then transplanted into busulfan-treated mouse

* Correspondence: lixiaoyu1226@gmail.com; liuyx@ioz.ac.cn

†Xiaoyu Li and Tiecheng Sun contributed equally to this work.

¹Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China

²State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China



testes for spermatogenesis re-establishment. This is an encouraging strategy which can produce functional haploid cells for intracytoplasmic sperm injection (ICSI). However, since ICSI is still needed to get offsprings, the azoospermia has not been completely cured in fact. Besides, the whole treatment process is so cumbersome that it is difficult to be applied in clinical treatment for patients.

The feasibility of CRISPR-Cas9-mediated gene editing in spermatogonial stem cells (SSCs) has been reported [11, 12]. Transplanted SSCs can generate complete spermatogenesis in recipient testis [13]. If we can carry out CRISPR-Cas9-mediated gene correction on SSCs taken from NOA patients, the treatment process will be greatly simplified, the risk of tumor formation will be reduced, and even the patients are able to restore natural fertility.

Here, to explore the feasibility of this strategy, we improved our lab's established method for isolating SSCs [14, 15]; so that we can isolate SSCs from single unilateral juvenile *Kit^w/Kit^{wv}* mouse testis, CRISPR-Cas9-mediated homology-directed repair (HDR) was conducted on isolated mutant SSCs. The repaired SSCs without *WV* mutation were screened out and propagated, then transplanted into another testis of the donor mouse. Healthy offsprings were obtained through natural mating 4 months after repaired SSC were transplanted. This work provides a more convenient and more humane therapeutic strategy for NOA.

Method

Animals

Kit^w/Kit^{wv} and C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The use of mice and all pertinent surgical procedures were approved by the Animal Care and Use Committee of the Institute of Zoology, Chinese Academy of Sciences.

SSC cultures, gene editing, and transplantation

One-step enzymatic digestion with collagenase I (GIBCO) and DNase I (AppliChem) was used for isolation of testicular cells from ~14 days postpartum (dpp) mice to small seminiferous tubule fragments. The fragments were plated on 100-mm dishes in mouse embryonic fibroblast (MEF) medium, one dish for one testis. Then dishes were observed under a microscope after 18 h of culture. Dishes containing germ cells were screened out, loosely attached germ cells were collected with repetitive pipetting, and these germ cells were found to migrate into the culture dish. Thereafter, cells were transferred to new freshly prepared mouse embryonic fibroblast (MEF) dish to enrich SSC cultures. SSCs were cultured in the serum-free MEM α (Invitrogen)

supplemented with 25 μ g/ml insulin (Sigma), 100 μ g/ml transferrin (Sigma), 20 μ g/ml putrescine (Sigma), 3 mg/ml BSA (ICN), 20 μ g/ml ascorbic acid (Sigma), 2 mM L-glutamine (GIBCO), 55 μ M 2-mercaptoethanol (Sigma), 10 mM HEPES (Sigma), 50 units/ml penicillin (Sigma), 50 μ g/ml streptomycin (Sigma), 20 ng/ml human GDNF (R&D), and 5 ng/ml human bFGF (Peprotech). The enriched SSC cultures were passaged every 4 to 5 days at a dilution of 1:2 to 1:4 depending on the size of the cell clumps and the growth of the somatic cells to remove testicular somatic cells in each passage. As such, relatively pure mutant SSC clumps, which have 93% GFRA-1-positive cells and 3% c-Kit-positive cells as reported earlier (14), were routinely obtained after a total of ~4–5 passages.

The *WV*-sgRNA was designed and selected from <http://crispor.tefor.net/>, then cloned into Bbs I sites of pX458 plasmids (Addgene plasmid 48138). This plasmid and oligo DNA were transfected into SSCs with Amaxa Cell Line Nucleofector Kit L (Lonza) using Amaxa Nucleofector according to the manufacturer's instruction.

For transplantation, SSC clumps were trypsinized into single cells and prepared in concentrations of 5×10^7 cells/ml for SSC transplantation. Ten microliters cell suspension were injected into each testis of *Kit^w/Kit^{wv}* mice via the efferent duct.

Off-target effect analysis

We identified a total of 41 potential "off-target" sites by the website used in gRNA design. We examined the five highest scoring sites. DNA sequencing of PCR products amplified from these genomic sites was performed on three different passages of the successfully repaired SSC line. The five highest scoring sites and sequences of the primers for the amplification of these five off-target sites were as follows: intergenic of *Lca5* and *Sh3bgrl2* (Forward-CAGAGG CACCTGCACTT, Reverse-TGGAACCCATCCTAACG); intergenic of *Gm1815* and *Zfp353* (Forward-GTCCAC ATCACATCTCA, Reverse-ACATCGGACTTTACCTT); intergenic of *Kif2b* and *Gm11498* (Forward-CGCTGG CTCTATGCTTA, Reverse-CCCAAAGTGGTGGTGAG); intergenic of *Epha4* and mmu-mir-6352 (Forward-GTCCTCAAATCCACAA, Reverse-GGGCTATTAA TCAACAA); intron of *Dagla* (Forward-AGCTCTTCAG ATTCCCC, Reverse-TCCAGACTCTATCCCC).

Immunofluorescence microscopy

Testes collected from *Kit^w/Kit^{wv}* mice 2 months after SSC transplantation were fixed overnight in 4% paraformaldehyde and embedded in paraffin. Tissue sections (5 μ m in thickness) were obtained in a microtome and mounted on glass slides. Sections were dewaxed and rehydrated, followed by antigen retrieval in 10 mM

sodium citrate buffer. After blocking with 5% BSA in PBS (wt/vol) for 1 h, the sections were incubated with primary antibody at 4 °C overnight (see Table 1). Secondary antibody conjugated with either FITC or TRITC (Jackson ImmunoResearch) at 1:200 dilution was used and incubated for an hour at room temperature. Slides were then stained with DAPI (blue) to visualize cell nuclei and mounted in prolonged anti-fade mounting medium. Fluorescence images were captured using a Zeiss LSM780 confocal microscope.

Genotyping

We used phenotypes to determine genotypes for the *Kit^w/Kit^{wv}* mouse and related strains according to the “Genotyping Protocol” provided by The Jackson Laboratory. The hybrid *Kit^w/Kit^{wv}* mice are the offspring of a cross between *Kit^w/Kit⁺* (Stock No. 000692) females and *Kit^{wv}/Kit⁺* (Stock No. 000049) males. The *Kit^w/Kit⁺* mouse is black with a white belly spot, occasionally has a white head blaze, and tail has a white tip. The *Kit^{wv}/Kit⁺* mouse is gray with a light belly and white spot and a light tail. However, the *Kit^w/Kit^{wv}* mouse has a white coat and black eyes. Researchers can easily distinguish these three strains of mice by their different coat color characteristics.

Bisulfite sequencing

To confirm the DNA methylation state, bisulfite sequencing was performed using the EZ DNA methylation kit (Zymo Research) following the manufacturer’s manual. Primers for bisulfite sequencing used in this study were as follows: *H19* (Forward-TATGAGTATT TAGGAGGTAT AAGAATT, Reverse-TTTTATCAAA AACTAACATAAACCCCT); *H19 nest* (Forward-TGT AAGGAGATTATGTTTTATTTTTGG, Reverse-CCC TAACCTCATAAAACCCATAAC TAT); *Snrpn* (Forward-TATGAGTATTTAGGAGGTATAAGAATT, Reverse-AA TAAACC AAATCTAAAATATTTAATC); *Snrpn nest* (Forward-AATTTGTGTGATGTTTGTAATTAT TTGG,

Reverse-ATAAAATACACTTTCCTACTACTAAAATCC). To determine the methylation state of individual CpG sites, the PCR product was extracted from the agarose gel, subcloned into a pClone007 vector (TSINGKE), and then sequenced for subsequent analysis.

Results

Isolation of SSCs from one *Kit^w/Kit^{wv}* testis

The overall experiment process of this study is shown in Fig. 1. Gene-defective SSC isolation was the first step. Some of the *Kit^w/Kit^{wv}* mutant testes completely lack spermatogonia, and the remaining testes contained only a few spermatogonia [16], which leads us unable to isolate SSCs as usual [15], so a donor testis screening procedure was added to the SSC isolation process. Besides, in order to ensure mouse survival after removal of unilateral testis and convenient to surgical operation, 14-dpp (day postpartum)-old mice were used. Unilateral testes taken from donor mice were digested into small seminiferous tubule fragments and respectively plated on dishes for 18 h. Most empty tubules are shown as the lower left panel of Fig. 2a, except for tubules containing spermatogonia shown as the upper right panel of Fig. 2a. Only the testis in which spermatogonia could be observed under an inverted microscope was selected for subsequent SSC separation and enrichment experiments. The obtained *Kit^w/Kit^{wv}* mutant SSCs clone had normal cell morphology (Fig. 2b), and their SSC identity were confirmed by positive immunostaining of germ cell’s marker Tra98 and stem cell’s GFR α -1, and negative immunostaining of differentiated germ cell’s marker c-Kit; all these SSC identities were consistent with wild type SSCs (Fig. 2c). The presence of *W* and *WV* point mutations on isolated SSCs were confirmed by DNA sequencing analysis (Fig. 3a).



WV point mutation correction

Since *Kit^w/Kit⁺* and *Kit^{wv}/Kit⁺* mice were fertile [17], and as long as one of the two mutation sites is repaired, the *Kit^w/Kit^{wv}* SSCs will restore the differentiation ability. We chose *WV* point for gene editing because there was an NGG sequence near its 3’ end. The schematic of sgRNA targeting is illustrated in Fig. 3b. We designed the single-guide RNA (sgRNA) targeting the *WV* point (termed *WV*-sgRNA) which could guide Cas9 to cut the DNA strand just at the C to T mutant site (*WV* mutation point). In order to improve the incidence of HDR, 130-bp donor DNA, whose “*WV* point” was unmutated, and pX458 plasmids expressing Cas9, GFP reporter, and *WV*-sgRNA were co-transfected into *Kit^w/Kit^{wv}* SSCs. One day after electroporation, transfected SSCs were enriched by flow cytometry depending on their fluorescence

Table 1 Antibodies used in this study

Antibody	Vendor	Catalog no.	Host	Working dilution
Tra98	Abcam	Ab82527	Rat	1:200
GFR α -1	R&D	AF560	Goat	1:200
C-kit	Abcam	Ab5506	Rabbit	1:200
SCP3	Abcam	Ab97672	Mouse	1:200
N-cadherin	Santa Cruz	sc-7939	Rabbit	1:200
JAM-A	Thermo	36-1700	Rabbit	1:200
Lin28a	R&D	AF3757	Goat	1:200
SOX9	Abcam	ab76997	Mouse	1:200

Abcam, Cambridge, UK; Santa Cruz Biotechnology, Dallas, TX, USA; Thermo Fisher Scientific, Waltham, MA, USA; R&D Systems, Minneapolis, MN, USA






Fig. 3 HDR-mediated correction of WV point mutation. **a** DNA sequencing of the W and WV point mutation loci in the *Kit^W/Kit^{WV}* SSC cell line. Both two mutation sites showed two peaks. **b** Schematic of the Cas9-sgRNA targeting and gene correction via HDR in WV point mutation loci. Blue line labeled the sgRNA-targeting sequences and the mutant base was marked in red. **c** DNA sequencing of the WV point mutation loci in repaired *Kit^W/Kit^{WV}* SSC cell line showed HDR-mediated repair gene-editing event. **d** DNA sequencing of the WV point mutation loci in typical error-repaired *Kit^W/Kit^{WV}* SSC cell line showed NHEJ-mediated “CACG” deletion. **e** Methylation analysis of the DMRs of H19 and Snrpn in *Kit^W/Kit^{WV}* SSCs and WV point mutation repaired SSCs. The result indicated that the repaired SSCs maintained paternal genomic imprints. Open and filled circles represent un-methylated and methylated CpG sites, respectively

characteristics and plated at low density on plates. Then single SSC colonies were picked up, and each colony was cultured in one well of the 48-well culture plate for further expansion and sequenced to screen the successfully repaired SSC lines when each clone had expanded to 2×10^3 cells during passage. Twenty-one successfully expanded single SSC colonies were detected when the repaired SSC clone was screened out. Both HDR-mediated repair (one SSC clone) and nonhomologous end joining (NHEJ)-mediated deletion gene-editing events (three SSC clones) were detected after the CRISPR-Cas9 induction on the WV mutation site (Fig. 3c, d). Then, the SSC clone with repaired WV locus was screened out for further research (Fig. 3c). This SSC clone maintained paternal genomic imprints (Fig. 3e). Besides, we examined the five highest scoring potential “off-target” sites by DNA sequencing of the PCR products amplified from these genomic sites; no obvious off-target mutations were detected (Fig. 4).

Assembly of normal blood–testis barrier (BTB) after repaired SSC transplantation and differentiation

The BTB is one of the essential prerequisites for spermatogenesis to proceed smoothly [18]. *Kit^W/Kit^{WV}* mice cannot establish a functional BTB to support meiosis due to *c-Kit* mutation usually, but the transplantation of normal SSCs can induce its assembly [15]. In order to examine if the SSCs with repaired WV locus could induce the assembly of functional BTB in *Kit^W/Kit^{WV}* mice, the repaired SSCs were harvested and transplanted into adult *Kit^W/Kit^{WV}* mice after being cultured for several passages. Then, the recipient mice were euthanized for examination by immunofluorescence analysis of typical BTB constituent proteins N-cadherin and JAM-A in the next 8 weeks so that the status of BTB assembly in cross sections of seminiferous tubules was carefully monitored. As anticipated, the functional BTB assembly was conditionally induced as normal SSCs are transplanted [15], which was directly related to the differentiation stage of germ cells within specific domains of the





Fig. 4 Off-target effect analysis. Sequences of the five highest scoring potential "off-target" sites were labeled with red. DNA sequencing of PCR products amplified from these genomic sites was performed. The results of DNA sequencing were consistent with corresponding genome sequences. No obvious off-target mutations were detected

seminiferous epithelium. In tubules without germ cells, the distribution of N-cadherin and JAM-A was diffusely localized and extended all the way to the tubule lumen. However, they were restrictively expressed to the site in the basal region of the seminiferous epithelium where SSCs had differentiated into spermatocytes and round spermatids (Fig. 5), consistent with their location at the BTB in normal wild type control testes.

Establishment of complete spermatogenesis and generation of healthy offsprings after repaired SSC transplantation

After confirming that the SSCs with repaired *WV* locus could successfully induce the assembly of functional BTB and differentiate in *Kit^w/Kit^{wv}* mice, we examined if the

recipient mice could establish complete spermatogenesis, and restoring fertility, the repaired SSCs were transplanted into another testis of the donor mouse and other 14 adult *Kit^w/Kit^{wv}* mice. Unrepaired *Kit^w/Kit^{wv}* SSCs were also transplanted as control. Two months later, three recipient mice of the repaired SSCs were sacrificed for spermatogenesis status detection. We observed that both kinds of SSCs recolonized to the basement membrane and proliferated. However, unrepaired *Kit^w/Kit^{wv}* SSCs were still positive for spermatogonia marker Lin28a and could not differentiate to establish complete spermatogenesis (Fig. 6A, a). But the repaired SSCs could differentiate further and establish complete spermatogenesis in seminiferous cords (Fig. 6A, b). The distribution pattern of germ cells in the repaired SSC recipient testes was consistent with that in



wild type testes (Fig. 6A, d), but significantly different from that in *Kit^w/Kit^{wv}* testes lacking germ cells (Fig. 6A, c). Then, wild type and *Kit^w/Kit⁺* offsprings were obtained from the donor mouse and other 9 of 11 adult *Kit^w/Kit^{wv}* recipient mice after mating with wild type C57BL/6 mice (Fig. 6B), which means the NOA of the *Kit^w/Kit^{wv}* mouse was cured.

Discussion

CRISPR-cas9-mediated gene editing has been applied on mouse and rat SSCs for the acquisition of healthy offsprings from parents with somatic cell genetic disease [11, 12]. This treatment strategy is promising and relatively easy to implement, because these “patients” had normal spermatogenesis to provide enough SSCs. However, it may not be suitable for NOA patients who lack germ cells. In contrast, our study has brought great hope for NOA patients with germ cell genetic disease. If their SSCs can be isolated through testicular biopsy [19] and corrected in vitro, then transplanted back to the patients’ withered testes to restart spermatogenesis, the NOA will be cured. In this study, we verified the feasibility of this treatment strategy. The establishment of complete spermatogenesis in the recipient testis after repair of SSC

transplantation and generation of healthy offsprings indicated the feasibility of this strategy.

This strategy only includes SSC isolation, in vitro gene editing, and transplantation, three main steps which are greatly simplified compared to a previous report [9]. Besides, autologous transplantation is more ethical and immunotoxic reactions are removed. SSC cell lines that carry the desired gene modification without unwanted mutations can be selected easily in vitro, which brings a 100% efficiency of birth to healthy offsprings [11]. Somatic cell genetic disease also have a chance to be removed from offsprings in this treatment process. Furthermore, this strategy is more ethical and easier to be accepted for NOA patients. If it can be applied in humans, the NOA will be cured actually, which means that the patients can give birth according to their own wishes by the way of natural mating. For NOA patients without SSCs, the strategy of Yuan et al. is more applicable.

As mentioned above, this strategy is mainly aimed at the treatment of NOA caused by germ cell gene defects, especially these NOA patients whose testes have intact or partially intact stem cell niche and retained SSCs. It may not be the most suitable or economical treatment strategy for other types of NOA patients, such as




Fig. 6 Natural fertility restoration after repaired SSC transplantation. **A** Spermatogenesis status of recipient testes 2 months after mutant or repaired SSC transplantation. The germ cells in *Kit^w/Kit^{wv}* SSC recipient testes are positive for spermatogonia marker Lin28a (green) and cannot complete meiosis. In contrast, complete spermatogenesis can be found in recipient testes of repaired SSCs. The distribution pattern of germ cells in *Kit^w/Kit^{wv}* testes and wild type testes were also detected by immunostaining of germ cell marker Tra98 (red) as controls. Scale bar = 50 μ m in original size panels and 25 μ m in magnified panels. **B** The offsprings derived from transplanted repaired SSCs

azoospermic cancer survivors whose testicular stem cell niche is compromised.

Although we co-transfected a donor DNA to improve the incidence of HDR, the 4.7% (1/21) incidence rate of HDR was still low and lower than the incidence rate of NHEJ 14.2% (3/21). More efforts should be made to improve the incidence of HDR. Satisfactorily, the recipient mice had a high rate (81.8%) of successful reproduction rate after mating with wild type C57BL/6 mice, which means the repaired SSCs had a great chance to successfully restore spermatogenesis.

Researchers have made a lot of effort to reduce the off-target effect in recent years' application of the CRISPR-cas9 system, and relatively good results have also been achieved [20, 21]. However, unpredictable and unexpected mutations after CRISPR-Cas9 editing still occur. Although no obvious off-target mutations were detected in this study, the detection scheme we used was relatively simple and not comprehensive enough. There may be off-target events that had not been detected. So stricter standards must be used if this strategy is used in a human body. More comprehensive and detailed inspection methods,

such as whole genome sequencing, must be used before transplantation.

The propagation of human SSCs *in vitro* was reported about 10 years ago [22, 23], but there are still difficulties for other labs to replicate. So, we cannot apply this strategy on human NOA patients immediately, but we believe SSCs will play a key role in getting human offsprings without genetic disease in the near future.

Conclusions

In this study, we established a new treatment strategy for NOA caused by germ cell gene defects through combination of SSC isolation, CRISPR-Cas9-mediated gene editing, and SSC transplantation, which brought hope for some NOA patients to restore their natural fertility. Not only to cure the NOA patients with germ cell gene defects, but may also for males who can bear normally but with other genetic disorders, be able to produce normal gametes and descendants by combining this strategy and ART technology.

Abbreviations

BTB: Blood–testis barrier; dpp: Day postpartum; HDR: Homology-directed repair; ICSI: Intracytoplasmic sperm injection; MEF: Mouse embryonic fibroblast; NHEJ: Nonhomologous end joining; NOA: Nonobstructive azoospermia; sgRNA: Single-guide RNA; SSCs: Spermatogonial stem cells

Acknowledgements

Not applicable.

Authors' contributions

XL performed the study design, most experiments, and manuscript writing. TS participated in the data analysis and manuscript modification. XW was the main handler of SSC transplantation. YL participated in the study design and manuscript modifications and supervised the study. Other colleagues participated in the article modifications. All authors read and approved the final manuscript.

Funding

This work was supported by grants from Major Research Plan "973" Project (2012CB944702), Natural Science Foundation of China (31501161 and 31471352).

Availability of data and materials

All analyzed data are available in the manuscript. Raw data or other materials produced in the conduct of these studies are available from the authors to qualified investigators upon request.

Ethics approval and consent to participate

The use of mice and all pertinent surgical procedures were approved by the Animal Care and Use Committee of the Institute of Zoology, Chinese Academy of Sciences.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 8 July 2019 Revised: 4 August 2019

Accepted: 15 August 2019 Published online: 24 August 2019

References

- Bhasin S, de Kretser DM, Baker HW. Clinical review 64: pathophysiology and natural history of male infertility. *J Clin Endocrinol Metab.* 1994;79(6):1525–9.

- Kumar R. Medical management of non-obstructive azoospermia. *Clinics.* 2013;68(Suppl 1):75–9.
- Sadri-Ardekani H, Atala A. Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside. *Stem Cell Res Ther.* 2014;5(3):68.
- Miyamoto T, et al. Male infertility and its genetic causes. *J Obstet Gynaecol Res.* 2015;41(10):1501–5.
- Elliott DJ, et al. Expression of RBM in the nuclei of human germ cells is dependent on a critical region of the Y chromosome long arm. *Proc Natl Acad Sci U S A.* 1997;94(8):3848–53.
- Yatsenko AN, et al. Non-invasive genetic diagnosis of male infertility using spermatozoal RNA: KLHL10 mutations in oligozoospermic patients impair homodimerization. *Hum Mol Genet.* 2006;15(23):3411–9.
- Miyamoto T, et al. Azoospermia in patients heterozygous for a mutation in SYCP3. *Lancet.* 2003;362(9397):1714–9.
- Soini S, et al. The interface between assisted reproductive technologies and genetics: technical, social, ethical and legal issues. *Eur J Hum Genet.* 2006; 14(5):588–645.
- Yuan Y, et al. Generation of fertile offspring from Kit(w)/Kit (wv) mice through differentiation of gene corrected nuclear transfer embryonic stem cells. *Cell Res.* 2015;25(7):851–63.
- Chabot B, et al. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. *Nature.* 1988; 335(6185):88–9.
- Wu Y, et al. Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. *Cell Res.* 2015;25(1):67–79.
- Chapman KM, et al. Targeted germline modifications in rats using CRISPR/Cas9 and spermatogonial stem cells. *Cell Rep.* 2015;10(11):1828–35.
- Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. *Proc Natl Acad Sci U S A.* 1994;91(24):11298–302.
- Zhang Y, et al. Endogenously produced FGF2 is essential for the survival and proliferation of cultured mouse spermatogonial stem cells. *Cell Res.* 2012;22(4):773–6.
- Li XY, et al. Regulation of blood-testis barrier assembly *in vivo* by germ cells. *FASEB J.* 2018;32(3):1653–64.
- Ohta H, Tohda A, Nishimune Y. Proliferation and differentiation of spermatogonial stem cells in the w/wv mutant mouse testis. *Biol Reprod.* 2003;69(6):1815–21.
- Nocka K, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. *EMBO J.* 1990;9(6):1805–13.
- Mruk DD, Cheng CY. The mammalian blood-testis barrier: its biology and regulation. *Endocr Rev.* 2015;36(5):564–91.
- Yang S, et al. Generation of haploid spermatids with fertilization and development capacity from human spermatogonial stem cells of cryptorchid patients. *Stem Cell Reports.* 2014;3(4):663–75.
- Slaymaker IM, et al. Rationally engineered Cas9 nucleases with improved specificity. *Science.* 2016;351(6268):84–8.
- Nishimasu H, et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. *Science.* 2018;361(6408):1259–62.
- Sadri-Ardekani H, et al. Propagation of human spermatogonial stem cells *in vitro*. *Jama.* 2009;302(19):2127–34.
- He Z, et al. Isolation, characterization, and culture of human spermatogonia. *Biol Reprod.* 2010;82(2):363–72.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.